Table 2.
Cardiovascular Events.*
| End Point | Overall (N = 19,114) | Aspirin (N = 9525) | Placebo (N = 9589) | Hazard Ratio (95% CI) | ||
|---|---|---|---|---|---|---|
| no. of participants with event | no. of participants with event | rate per 1000 person-yr | no. of participants with event | rate per 1000 person-yr | ||
| Cardiovascular disease† | 922 | 448 | 10.7 | 474 | 11.3 | 0.95 (0.83–1.08) |
| Major adverse cardiovascular event‡ | 701 | 329 | 7.8 | 372 | 8.8 | 0.89 (0.77–1.03) |
| Fatal cardiovascular disease§ | 159 | 78 | 1.8 | 81 | 1.9 | 0.97 (0.71–1.33) |
| Hospitalization for heart failure | 171 | 88 | 2.1 | 83 | 1.9 | 1.07 (0.79–1.44) |
| Fatal or nonfatal myocardial infarction | 355 | 171 | 4.0 | 184 | 4.3 | 0.93 (0.76–1.15) |
| Fatal or nonfatal ischemic stroke¶ | 315 | 148 | 3.5 | 167 | 3.9 | 0.89 (0.71–1.11) |
Because some end points were composites, a participant who had events for more than one component of the composite (e.g., stroke and then acute myocardial infarction) would contribute only the first event that occurred to the composite end point but would contribute an event to the separate analyses of each component. Hence, summation of the number of events for separate components of a composite end point does not equate to the number of events for the composite end point. The confidence intervals shown in this table have not been adjusted for multiple comparisons, and inferences drawn from them may not be reproducible.
Cardiovascular disease, a prespecified secondary end point, was a composite of fatal coronary heart disease (death from myocardial infarction, sudden cardiac death, or any other death in which the underlying cause was considered to be coronary heart disease), nonfatal myocardial infarction, fatal or nonfatal stroke (including hemorrhagic stroke), or hospitalization for heart failure.
Major adverse cardiovascular events, a nonprespecified end point, was a composite of fatal coronary heart disease (excluding death from heart failure), nonfatal myocardial infarction, or fatal or nonfatal ischemic stroke.
Fatal cardiovascular disease was defined as any death from stroke (including hemorrhagic stroke) or coronary heart disease.
Data for ischemic stroke included cases that were adjudicated as ischemic stroke, cases for which stroke type was uncertain after adjudication, and cases of ischemic stroke with hemorrhagic transformation.